AlzeCure Pharma Investor Relations Material
Latest events
Status Update
AlzeCure Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from AlzeCure Pharma
Access all reports
AlzeCure Pharma AB (publ), a clinical-stage biopharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease; ACD857, ACD679 and ACD680 for Alzheimer's disease; ACD440 and TrkA-NAM for neuropathic pain; and DBS-10134 (ACD423) for migraine headache.
Latest articles
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
ALZCUR
Country
đžđȘ Sweden